SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics in All-Cash Deal
Wednesday, August 06, 2025
SERB Pharmaceuticals, a global specialty pharmaceutical company focused on rare diseases and medical emergencies, has entered into a definitive agreement to acquire Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a biopharmaceutical firm specialising in antibody-based cancer treatments. The all-cash transaction values Y-mAbs at approximately $412 million.
As part of the agreement, SERB will launch a tender offer to acquire all outstanding shares of Y-mAbs common stock at $8.60 per share. This represents a premium of around 105% over Y-mAbs’ closing share price on 4 August 2025, the last trading day before the announcement.
Y-mAbs’ Board of Directors approved the transaction unanimously after evaluating a range of strategic options to deliver value to shareholders. The review process included discussions with multiple potential acquirers for either the entire business or specific assets, including the company’s lead commercial therapy, DANYELZA® (naxitamab-gqgk), and its radiopharmaceuticals platform.
Y-mAbs is known for its focus on paediatric oncology and successfully brought DANYELZA to market. The treatment, which targets GD2, is the first therapy approved by the US FDA for relapsed or refractory high-risk neuroblastoma—a rare and aggressive childhood cancer. DANYELZA is approved under accelerated approval based on its response rate and duration of response and can be administered in both inpatient and outpatient settings.
The company’s pipeline also includes investigational treatments targeting GD2 in solid tumours and CD38 in circulating cancers, using its Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT), currently in Phase 1 clinical trials.
For SERB, the acquisition of Y-mAbs aligns with its strategy to expand its rare oncology portfolio, which already includes treatments such as Voraxaze®, Vistogard®, and Xermelo®. The addition of DANYELZA is expected to enhance SERB’s global reach and strengthen its offering in rare and difficult-to-treat cancers. The company intends to leverage its medical, regulatory, and commercial expertise to support broader access to the therapy.
This transaction also marks another step in SERB’s long-term growth strategy, following its earlier expansion into the United States. By combining capabilities, both companies aim to advance the availability of innovative cancer treatments to more patients worldwide.
Source: globenewswire.com
